Intercommunication of Dopamine Receptors (DRs) with their associate protein partners is crucial to maintain regular brain function in human. Majority of the brain disorders arise due to malfunctioning of such communication process. Hence, contributions of genetic factors, as well as phenotypic indications for various neurological and psychiatric disorders are often attributed as sharing in nature. In our earlier research article entitled "Human Dopamine Receptors Interaction Network (DRIN): a systems biology perspective on topology, stability and functionality of the network" (Podder et al., 2014) [1], we had depicted a holistic interaction map of human Dopamine Receptors. Given emphasis on the topological parameters, we had characterized the functionality along with the vulnerable properties of the network. In support of this, we hereby provide an additional data highlighting the genetic overlapping of various brain disorders in the network. The data indicates the sharing nature of disease genes for various neurological and psychiatric disorders in dopamine receptors connecting protein-protein interactions network. The data also indicates toward an alternative approach to prioritize proteins for overlapping brain disorders as valuable drug targets in the network.
a b s t r a c t
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Value of the data
The data hints an overlapping disease spectrum of neurological disorders in DRIN.
The data pinpoint towards common contributing genetic factors of neurological disorders in DRIN.
The data might encourage researchers to identify additional drug targets in DRIN for future drug discovery endeavors.
Data
The data highlighted 25848 associations between 431 proteins and 4312 diseases, disorders and clinical or abnormal human phenotypes in Dopamine Receptors Interactions Network (DRIN) [1] . The associations were refined through stringent statistical analysis to reduce the over representation of Fig. 1 . Gene-disease enrichment analysis in DRIN. In the plot the X-axis represents the percentage of genes associated with each disease terms in DRIN and Y-axis represents the enrichment statistics (P-value cut off o 0.05) of disease terms in DRIN. A total of 143 different disease terms were significantly identified (blue dots) over 4312 disease association in DRIN after bonferroni correction of the P-value (two-sided hypergeometric test). disease information in DRIN (Table S1 ). Further, related disease terms were combined together and significant associations of 29 disease modules in the DRIN were obtained (Figs. 1-3 ). The disease modules were classified based on the distributions of overlapping genetic factors (Figs. 4-7) . In addition, the common contribution factors for different brain disorders were characterized based on functional enrichment analysis to pinpoint additional drug targets in human DRIN (Figs. 8-10 ). Data were also tabulated to get more insights into drug availability for those targets (Fig. 11) . 
Experimental design, materials and methods

Disease enrichment data analysis
Genes were mapped to respective disease data using DisGeNet database [2] . The disease data indicates an association of diseases, disorders and clinical or abnormal human phenotypes with a given set of gene list. The data covers different biomedical aspects of each disease from several sources.
To identify significant enrichment of diseases in our data two-sided hypergeometric test [3] were carried out. The P-values were further corrected by the bonferroni correction (P r0.05) to determine a list of significant disease association in our data.
where N ¼Total number of genes in DisGeNet; n ¼Total number of genes in DRIN; m ¼Each disease associated genes in DisGeNet; x¼ Each disease associated genes in DRIN
Disease overlapping data analysis
Overlapping of genes between two diseases was measured using Jaccard or Tanimoto coefficient metrics [4] which compared the similarity and diversity of disease sets in our data. It uses the ratio of the intersecting set to the union set as the measure of similarity. Thus it equals to zero if there are no intersecting elements and equals to one if all elements intersect.
where N a ¼ number of elements in set A; N b ¼ number of elements in set B; N c ¼number of elements in intersecting set Based on the similarity matrix, the disease sets were further classified into different clusters using Neighbor Joining (NJ) algorithm which is a bottom-up or agglomerative clustering method to identify similar group of elements in the data [5] . The Phylip tool [6] was used to implement the NJ method in our data.
Functional classification of data
The pathways information and transcription factor (TF) regulatory data were collected from the Molecular Signatures Database (MSigDB) [7] . Regulatory data is represented as a bipartite graph between a set of genes and transcription factors. Data for expression profiling of TFs in different brain tissues were obtained from GTEx portal web server [8] .
Drug data analysis
A comprehensive search was made in DrugBank v4.0 (http://www.drugbank.ca/) database [9] to identify the known drugs related to our data set. Data was also obtained from a recent study by Rask-Andersen [10] , to arrange the genes based on approved, investigational, not approved and withdrawn drug information.
